(1) The majority of those (80%) become persistently infected and have an increased risk of developing liver disease, including fibrosis, cirrhosis, and hepatocellular carcinoma.
H epatitis C virus (HCV) has significant implications for global health given that an estimated 180 million individuals are infected.
(1) The majority of those (80%) become persistently infected and have an increased risk of developing liver disease, including fibrosis, cirrhosis, and hepatocellular carcinoma. (2) The propensity of HCV to establish persistent infection stems from multiple strategies to evade the immune system. (3) The liver is a primary site of replication and thereby recruited immune cells are subjected to the tolerogenic microenvironment and the immune-regulatory processes accompanied by HCV. Immunity during HCV infection is characterized by dysfunctional CD4 1 T help, (4, 5) impaired CD8 1 T cells, (6) and deficient humoral immunity.
A better understanding of HCV-mediated immune modulation will improve our understanding of how chronic infection is established and facilitate vaccine development.
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HCV patients and are positively correlated with viral load. (8, 9) Furthermore, abundant Tregs are found in livers of chronic HCV patients. (10, 11) A subset of Tregs, called T follicular regulatory (Tfr) cells, has been identified for functional regulation of germinal center (GC) responses by limiting T follicular helper (Tfh) cells and B cells. (12) (13) (14) Tfr cells are reported to be increased in the circulation of chronic HCV patients. (15) Tfr cells are identified by expression of follicular markers C-X-C chemokine receptor type 5 (CXCR5) and programmed death 1 (PD-1) and regulatory markers CD25 and forkhead box P3 (Foxp3). This allows Tfr cells to comigrate with Tfh to control GC responses. (16) Interestingly, lymphoid follicles, containing T and B cells, are commonly observed in livers of HCV patients and exhibit signs of GC-like architecture. (17, 18) Recent studies have identified the presence of Tfh within livers of HCV patients. (18, 19) However, whether Tfr cells are present in HCVinfected liver and their role and functionality have not been investigated.
In this study, we identified an unrecognized population of Tfr cells present within the livers of chronically infected HCV patients. Using an in vitro coculture system, we demonstrate that Tfr from healthy subjects undergo expansion following exposure to infected hepatocytes. Expansion of Tfr cells was accompanied by acquisition of an enhanced regulatory phenotype and leads to functional suppression of Tfh cells. Increases in Tfr responses were driven by a novel pathway involving release of transforming growth factor beta (TGF-b)-containing exosomes from HCV-infected hepatocytes. These findings highlight the accumulation of Tfr in livers of HCV patients, potentially inhibiting protective Tfh and B-cell responses at the site of infection, and contributing to viral persistence.
Materials and Methods

HUMAN SUBJECTS
Intrahepatic leukocytes from explanted liver tissue of HCV-infected patients (n 5 8), nonviral hepatitis (NVH) patients (n 5 6; nonalcoholic steatohepatitis, alcoholic liver disease, and autoimmune hepatitis) and healthy control subjects (n 5 7) and sera were provided by Dr. Hugo Rosen (University of Colorado). Briefly, intrahepatic leukocytes were isolated from liver tissues by first dissecting tissues into small fragments and then incubating with collagenase type IV as described. (37) Intrahepatic leukocytes were then cryopreserved and shipped from the University of Colorado. All participants of this study provided written informed consent and institutional review board (IRB) protocol 06-0566 was approved by the Colorado Multiple IRB.
HEPATOCYTES, HCV, AND PERIPHERAL BLOOD MONONUCLEAR CELL COCULTURES
The human hepatoma cell line, Huh7.5.1, was maintained in complete Dulbecco's modified Eagle's medium (DMEM). One day following seeding of hepatocytes, cells were infected with HCV (Japanense fulminant hepatitis type 1 [JFH-1] strain, genotype 2a) at a multiplicity of infection of 0.1. JFH-1 was kindly provided by Dr. Wakita (Tokyo Metropolitan Institute). For coculture, cryopreserved peripheral blood mononuclear cells (PBMCs) previously isolated from the buffy coats of healthy subjects (Virginia Blood Services, Richmond, VA) were resuspended in complete Roswell Park Memorial Institute medium
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(RPMI) and added to uninfected or HCV-infected hepatoma cells on day 4 postinfection or cultured alone for 4 days. In some experiments, tonsillar mononuclear cells (MNCs) were cocultured with uninfected or infected hepatocytes. Cryopreserved primary human hepatocytes (PHHs; Thermo Fisher Scientific, Waltham, MA) were cultured with Williams' Medium E and Hepatocyte Maintenance Supplement Pack on Collagen I-coated plates according to manufacturer protocols (Thermo Fisher Scientific) and were inoculated with HCV-infected patient sera. PHHs and PBMCs exhibited greater than >80% viability following cryopreservation and during experimentation.
FLOW CYTOMETRY AND T-CELL ISOLATIONS
Cells were stained with Zombie Aqua Fixable Viability dye (BioLegend, San Diego, CA). For identification of liver Tfr cells, surface staining was performed with the following antibodies: CD45-PerCP (peridinin-chlorophyll; Tonbo; 2D1, San Diego, CA); CD4-APC (allophycocyanin)/Cy7 (cyanine 7; Tonbo; RPA-T4); CD14-APC (eBioscience; 61D3, Waltham, MA); CD56-APC (eBioscience; CMSSB), CD11b-APC (BioLegend; ICRF44); CXCR5-BV421 (BioLegend; J252D4); PD-1/PE (phycoerythrin)/Cy7 (BioLegend; EH12.2H7); and CD25-FITC (fluorescein isothiocyanate; BD Biosciences; BC96). Following fixation with the Foxp3/Transcription Factor Fixation/ Permeabilization Kit (eBioscience), cells were stained with Foxp3-PE (eBioscience; 236A/E7). For intracellular cytokine analysis, cocultures were stimulated with 0.1 lg/mL of phorbol myristate acetate and 0.5 lg/mL of ionomycin (Sigma-Aldrich, St. Louis, MO) in the presence of GolgiPlug (BD Biosciences) for 4-6 hours. Cells were then surface stained with the following antibodies: CD4-APC/Cy7, CXCR5-BV421, and PD-1/ PE/Cy7. Following fixation with CytoFix/CytoPerm (BD Bioscience), cells were stained with interferon (IFN)-c/FITC (BioLegend; 4S.B3), interleukin (IL)-21/PE (eBioscience; eBio3A3-N2), or IL-17/PerCPeFluor710 (eBioscience; BL168). Intracellular staining of Tfr cells was performed by staining with Foxp3-APC (eBioscience; 236A/E7), IL-10/PE/Cy7 (BioLegend; JES3-9D7), and cytotoxic T-lymphocyteassociated protein 4 (CTLA-4)/PE (eBioscience; 14D3). CD4 T-cell isolations were performed by depleting CD14
1 monocytes using CD14 microbeads (Miltenyi, Auburn, CA) followed by positive selection with CD4 microbeads (Miltenyi). For depletion or sorting of Tfr, enriched CD4 T cells were stained with CD4-APC/Cy7, CXCR5-BV421, CD25-FITC or CD25-PE (BioLegend; BC96), and CD127-APC (eBioscience; eBioRDR5). CD4 T-cell isolations and Tfr/Tfh sorting procedures always yielded cell purities of at least 97%. 
SUPPRESSION ASSAYS
HEPATOCYTE EXOSOME ISOLATION AND PBMC CULTURE
Culture media from hepatoma cells or PHHs cultured with exosome-depleted serum was collected on day 4 or day 12 postinfection, respectively, and centrifuged at 1,500 rpm for 5 minutes. Supernatants were centrifuged at 2,500 rpm for 15 minutes. Media was then passed through 0.4-and 0.2-lm filters. Exosomes were precipitated by mixing with ExoQuick-TC (System Biosciences, Palo Alto, CA) and incubated overnight. Exosomes were pelleted and resuspended in phosphate-buffered saline. Exosomes were indirectly quantified by measuring total protein by bicinchoninic acid assay and concentrations were standardized before treating PBMCs or CD4 T cells. For exosome treatments, PBMCs or CD4 T cells were activated with anti-CD3/anti-CD28 (0.1 lg/mL each) for 48 hours. Isolated exosomes (50 lg) were added and cultures were incubated for 4 days. In some experiments, exosomes were further purified by incubating overnight with CD63-FITC (BioLegend; H5C6) followed by anti-FITC selection and magnetic particles (StemCell Technologies, Vancouver, Canada). For flow cytometry, the Exosome-Human CD63 Isolation/Detection kit (Invitrogen) was used to capture exosomes, followed by staining with CD63-FITC and TGF-b/PE (IQ Products; TB21, The Netherlands).
STATISTICAL ANALYSIS
Flow cytometry FCS files were analyzed in FlowJo (v10, Ashland, OR). Statistical analyses were performed using GraphPad Prism 7 (GraphPad Software Inc., San Diego, CA). Mann-Whitney U tests were performed to compare groups of unpaired, nonparametric values. Two-tailed paired t tests were used to compare different experimental conditions of paired, parametric values or Wilcoxon tests for paired, nonparametric values. A P value of < 0.05 was considered significant.
Results
T FOLLICULAR REGULATORY CELLS ARE INCREASED IN THE LIVER DURING CHRONIC HCV INFECTION
Profoundly impaired CD4
1 T-cell responses are associated with chronic HCV infection. Interestingly, Tfh cells in livers of chronically infected patients appear to be engaged in GC-like lymphoid follicles. (18, 19) However, the function of Tfh in regulating antiviral immune responses to HCV within liver GCs is unclear. Given that Tfr cells are critical regulators of Tfh/GC reactions, we hypothesize that HCV infection may trigger induction and/or expansion of Tfr in the liver microenvironment. We sought to determine the presence of Tfr in livers of chronically infected HCV patients. Flow cytometry was performed to analyze Tfh and Tfr populations within liver MNC preparations, as shown in Fig. 1A and Supporting Fig. S1 . As expected, frequency of CD4 1 T cells was significantly increased in HCV and NVH patients compared to healthy subjects (Fig. 1B) . Consistent with recent reports, (18, 19) we observed
Tfr cells, whereas there were little to no Tfr cells detectable in NVH and healthy subject controls (Fig. 1A,D) . These results suggest that Tfr may play a pivotal role in suppression of host immune responses to HCV infection, particularly Tfh responses in the liver microenvironment.
HCV INFECTION IN HEPATOCYTES LEADS TO EXPANSION OF T FOLLICULAR REGULATORY CELLS
To understand how HCV infection induces accumulation of Tfr cells in livers of chronically infected patients, we assessed the contribution of liver parenchymal cells. Given that infection and replication primarily occur in hepatocytes, we sought to determine the ability of HCV-infected hepatocytes to promote Tfr accumulation. To address this, we utilized an established coculture system of PBMCs from healthy individuals with HCV-infected hepatoma cells. Hepatoma cells were infected with HCV for 4 days. PBMCs were cocultured with uninfected or infected hepatoma cells, or cultured alone for 4 days. Following coculture, PBMCs were analyzed by flow cytometry and Tfr frequency was determined ( Fig. 2A) . Frequency of CD4
1 T cells was similar in all groups (Fig. 2B) , whereas frequency of CXCR5 1 PD-1 1 cells in HCV-infected cocultures was significantly increased compared to uninfected controls and PBMCs cultured alone (Fig. 2B) . Moreover, there was a significant increase in the percentage of Tfr following exposure to HCV-infected hepatocytes ( Fig. 2A,B) as well as increased expression levels of Foxp3 in Tfr cultured with infected hepatocytes (Fig. 2B) . Consistent with previous studies, (20, 21) the Treg population (CD4
1 ) was increased following coculture with infected hepatocytes.
To confirm the ability of HCV infection to induce Tfr accumulation, we performed experiments using cells obtained from human tonsils, which are secondary lymphoid tissue and contain a high proportion of Tfh and Tfr cells. Tonsillar CD4
1 T cells exhibited a traditional Tfh phenotype with high expression of CXCR5 and PD-1 (Fig. 2C) . Tonsillar MNCs showed no difference in percentage of CD4 1 T cells or Tfh (Fig. 2D) . However, the percentage as well as the number of Tfr was significantly increased in the HCV infection coculture compared to uninfected hepatocytes (Fig. 2C,D) . Tfr exposed to infected hepatocytes also up-regulated Foxp3 (Fig. 2D) . Thus, similar to PBMCs, tonsillar Tfr underwent expansion following exposure to HCV-infected hepatoma cells. These results demonstrate that HCV infection in hepatocytes may contribute to the increase in Tfr found in liver tissues of patients chronically infected with HCV.
Although Tfr cells are primarily thought to originate from thymic-derived Tregs, (16) it was recently reported that Tfr can differentiate from non-Treg precursors. (22) We tested the possibility of whether the increase in Tfr was attributed to differentiation from a non-Tfr population (i.e., CXCR5 -Tregs or CXCR5 and TGF-b, and expression of CTLA-4. (23) (24) (25) We evaluated the expression of these factors by tonsillar Tfr following coculture with HCV-infected or uninfected hepatocytes. The percentage of IL-10-producing Tfr was significantly increased following exposure to HCV-infected hepatocytes compared to uninfected hepatocytes (Fig. 3A,B) . As expected, Tfh produced minimal levels of IL-10 and was not increased by exposure to infected hepatocytes (Fig.  3C) . Additionally, Tfr from HCV-infected hepatocytes up-regulated CTLA-4 compared to Tfr from uninfected hepatocytes (Fig. 3D,E) . However, we did not observe any difference in intracellular TGF-b in Tfr (data not shown). These data indicate that HCV infection in hepatocytes leads to expansion of Tfr cells with increased suppressor function.
Tfr inhibit Tfh responses by suppressing activation, proliferation, and cytokine production. (16) To investigate the impact of increased Tfr responses, the functionality of Tfh was evaluated following exposure to HCV-infected hepatocytes. Circulating or memory Tfh found in PBMCs contain subsets that produce IL-21, IFN-c, or IL-17.
(26) Therefore, we evaluated the ability of Tfh to produce these cytokines following coculture with infected hepatocytes. There was a significant decrease in the percentage of IL-21-producing Tfh when exposed to HCV-infected hepatocytes relative to uninfected hepatocytes (Fig. 4A,B) . Importantly, mean fluorescence intensity (MFI) of IL-21 was also significantly reduced in Tfh cultured with HCV-infected hepatocytes (Fig. 4B) . The percentage of Tfh producing IFN-c or IL-17 was not affected (Fig. 4C,D) ; however, the level of IFN-c expression per cell was significantly reduced as evidenced by a decrease in MFI (Fig. 4C ). These results demonstrate that the ability of Tfh to produce IL-21 and IFN-c was impaired following exposure to HCV-infected hepatocytes. Despite diminished cytokine production, Tfh exhibited a significant increase in inducible T-cell costimulatory (ICOS) expression, a costimulatory molecule involved in Tfh activation and functionality, upon coculture with HCV-infected hepatocytes (Fig.  4E,F) (Fig. 5A,B) , although these results were not statistically significant, likely attributed to the presence of increased CXCR5 -PD-1 -Tregs despite Tfr depletion. We next determined a direct role of HCV-induced Tfr in suppression of Tfh by performing a suppression assay. Following coculture with infected hepatocytes, tonsillar Tfr cells were fluorescence-activated cell sorting sorted and then cultured at a 1:1 or 1:10 ratio with CFSE-labeled autologous Tfh not previously exposed to HCV. Tfh cultured with Tfr derived from HCVinfected hepatocyte cocultures proliferated significantly less than Tfh alone (Fig. 5C,D) . These results demonstrate that enhanced Tfr responses observed following exposure to HCV-infected hepatocytes can directly suppress Tfh responses.
EXOSOMES FROM HCV-INFECTED HEPATOCYTES CAN PROMOTE Tfr EXPANSION AND LEAD TO REDUCED Tfh FUNCTIONALITY
Hepatocytes infected with HCV release soluble mediators, such as TGF-b, that promote the development or enhancement of Treg responses. (20) Interestingly, several recent reports have demonstrated important roles for exosomes, secreted extracellular vesicles (<100 nm), in mediating cell-to-cell transfer of HCV infection between hepatocytes, and in activating myeloid cells through transfer of viral RNA. (27) (28) (29) Likewise, exosomes have a plethora of immunomodulatory activities, particularly tumor-cell-derived exosomes, on dampening T cell responses. (30, 31) Thus, we hypothesized that exosomes released from HCVinfected hepatocytes may have the ability to enhance Treg/Tfr responses in our system.
To evaluate the role of hepatic exosomes in promoting Tfr responses, we exposed PBMCs to secreted exosomes isolated from uninfected or HCV-infected hepatoma cells. The isolation of exosomes was confirmed by electron microscopy, western blotting, and flow cytometry for the exosomal marker, CD63 (Fig.  6A,B) . Treatment with exosomes from uninfected hepatocytes did not affect the percentage of Tfr compared to untreated controls. However, exposure of PBMCs to exosomes from HCV-infected hepatocytes led to an increase in the percentage of Tfr cells (Fig.  6C,D) . In some experiments, the effect of exosomes on Tfr was confirmed using isolated exosomes that were additionally purified by incorporating an anti-CD63 immuno-isolation step to rule out contamination of free virus within exosome preparations. Importantly, treatment of PBMCs and hepatocyte cocultures with the exosome release inhibitor, spiroepoxide, resulted in a significant reduction in the percentage of Tfr following exposure to HCV-infected hepatocytes (Fig. 6E) . Consistent with inhibition of IL-21 production by Tfh observed in the infected hepatocyte cocultures (Fig. 4A,B) , there was also a decrease in the percentage of IL-21
1 and IFN-c 1 cells following exosome exposure (Fig. 6F) . These results identify a novel pathway by which hepatocytes infected with HCV are able to influence adaptive immunity, through their release of immune-modulatory exosomes, leading to enhanced Tfr responses and diminished functionality in Tfh cells.
EXOSOMES FROM HCV-INFECTED HEPATOCYTES PROMOTE Tfr RESPONSES BY ACTING DIRECTLY ON CD4 T CELLS IN A TGF-b-DEPENDENT MANNER
We next wanted to determine whether exosomes interact directly with CD4
1 T cells to drive expansion of Tfr cells. In order to track interactions with immune cells, exosomes were labeled with CFSE and incubated overnight with PBMCs. Exosomes from uninfected and HCV-infected hepatoma cells readily interacted with CD4
1 T cells (Fig. 7A) . To determine whether exosomes directly engaging CD4
1 T cells would result in an increase in Tfr, exosomes were cultured with 
preactivated CD4
1 T cells for 4 days. Exposure of CD4 1 T cells to exosomes from HCV-infected hepatocytes led to a significant increase in Tfr, whereas treatment with exosomes from uninfected hepatocytes had no effect on Tfr percentage (Fig. 7B, left) . Next, we sought to confirm that PHHs also produce exosomes with immunosuppressive effects. Exosomes were isolated from uninfected or HCV-infected primary hepatocytes and cultured with preactivated infected primary hepatocytes, but not exosomes from uninfected hepatocytes, led to an increase in Tfr cells (Fig. 7B, right) . Given that HCV exosomes have recently been shown to induce monocyte differentiation, we wanted to determine that monocytes were not playing a role in Tfr cell responses. Depletion of CD14 1 monocytes before coculture did not affect the ability of infected hepatoma cells to induce Tfr cell expansion (Supporting Fig. S2 ), demonstrating that monocytes are not required and further supporting our results that exosomes act directly on CD4 T cells to drive Tfr responses.
TGF-b is important for induction and expansion of Tregs. (32, 33) However, the contribution of HCVinfected hepatocyte-derived TGF-b on Tfr cells has not been studied. TGF-b can be detected in exosomes of various sources. (34, 35) We hypothesized that, upon HCV infection, hepatocytes up-regulate expression of TGF-b in exosomes, which may act on T cells to promote Tfr responses. To determine whether exosomes released by infected hepatocytes contained more TGF- b, exosomes were isolated using CD63 immunoisolation, and then stained with anti-TGF-b antibodies. Exosomes were analyzed by flow cytometry to evaluate membrane-bound TGF-b. A small proportion of exosomes from uninfected hepatocytes were positive for TGF-b. However, significantly more exosomes from HCV-infected hepatocytes expressed TGF-b on their surface (Fig. 7C,D) .
To determine whether exosome-associated TGF-b could induce Tfr expansion following HCV infection, exosomes from uninfected and HCV-infected hepatocytes were first treated with anti-TGF-b blocking antibodies. Exosomes were then washed and incubated with CD4
1 T cells. As expected, treatment of CD4 1 T cells with exosomes from infected hepatocytes led to an increase in Tfr after 4 days (Fig. 7E,F) . Importantly, blockade of TGF-b on exosomes prevented the increase in Tfr (Fig. 7E,F ). These results demonstrate that the increased TGF-b-containing exosomes derived from HCV-infected hepatocytes can drive the expansion of Tfr by directly acting on T cells. These results highlight a novel mechanism by which HCV infection in hepatocytes shifts the immunomodulatory cargo of exosomes in a way that favors the expansion of Tfr cells.
Discussion
Numerous strategies for immune evasion, including increased T-cell exhaustion and regulatory T cells, are associated with chronic HCV infection. (3, 36, 37) However, mechanisms leading to CD4
1 T-cell dysfunction are yet to be completely defined. In this report, we identified Tfr cells in livers of chronic HCV patients, which were absent in healthy subjects and barely detectable, if at all, in NVH patients. There is growing interest in whether liver Tfh and the lymphoid-like structures they are associated with provide protection during infection. Given that GCs are tightly regulated by Tfr and that HCV has a propensity to facilitate Treg responses, exacerbated Tfr responses in the HCV-infected liver could suppress Tfh at the liver GCs. Accumulation of intrahepatic Tfr during infection could be attributed to the expansion of natural Tregs adopting a Tfr profile and/or potentially from HCV-specific differentiation and expansion. Results obtained from coculture studies support expansion from pre-existing Tfr. Further analysis of liver Tfr will be required to address whether they exhibit HCV specificity. Regardless, increased numbers of Tfr at the site of HCV infection will most certainly hinder Tfh function and potentially limit effective antibody responses within the liver.
We sought to understand the underlying mechanism contributing to the accumulation of Tfr. With the emergence of exosomes as central players in HCV pathogenesis and their expanding list of reported immunomodulatory activities, we hypothesized that liver exosomes could play a role in regulating immune cells during HCV infection. Interestingly, treatment of T cells with exosomes from HCV-infected hepatocytes resulted in an increase in the abundance of Tfr, which was dependent on exosome-associated TGF-b. This study highlights a novel pathway in which hepatocytes infected with HCV are able to release exosomes with the potential to promote the accumulation of Tfr.
Recently, several studies reported on the pathological role of Tfr cells in various disease settings such as human autoimmune disease and infection. Dysregulation of Tfr cells appears to be directly linked to the development of autoimmune diseases. (38) Interestingly, there is a high rate of human immunodeficiency virus (HIV) infection detectable in follicular lymphoid regions, resulting in dysregulated humoral immunity. As a result of HIV replication and TGF-b signaling, there was an increased frequency of Tfr cells, resulting in aberrant Tfh-cell responses and B-cell maturation. (39, 40) A striking observation from our study was the significant role that hepatocyte-derived exosomes play in regulating T-cell responses. Given that much of the immune modulation occurring during chronic HCV infection takes place within the liver, it underscores the importance of liver-derived exosomes and their role in intercellular communication. Exosomes have received much attention for their immuno-modulatory activities, which can include both activating and inhibitory effects on immune cells. (41) Exosomes from HCVinfected hepatocytes could contain other suppressive factors in addition to TGF-b. The cargo of exosomes can contain viral factors as well, including HCV-core and envelope proteins. (27) Thus, these exosomeassociated factors may contribute, to some degree, in the regulation of immune cells.
Whereas our study demonstrates direct effects of liver exosomes on CD4 1 T cells, it is possible that exosomes might act on other immune cells in the liver, including APC populations such as dendritic cells and macrophages, or liver sinusoidal endothelial cells. (42) Future studies will be critical to determine whether hepatocyte-derived exosomes modulate these cells and what the effects are on adaptive immunity and establishment of viral persistence. A limitation of our study is the use of exosomes from hepatocytes infected in vitro with HCV. The drawback to this approach is that exosome content and activity may not fully recapitulate exosomes secreted by infected hepatocytes in vivo during infection. In future studies, exosomes from biopsied primary hepatocytes could potentially be used to evaluate these effects in a more physiological setting. Second, circulating exosomes can be isolated from chronically infected patients to determine whether they contain higher levels of immuno-modulatory factors. Identification of this novel exosomal pathway responsible for Tfr expansion by HCV-infected hepatocytes could have implications for developing therapeutic strategies to alleviate excessive immune suppression and/or curtail viral transmission by exosomes.
The identification of Tfr cells in the livers of infected patients introduces an additional component of ongoing immune regulation during HCV infection that includes Tregs, tolerogenic DCs, and immunosuppressive viral factors. Although it is unclear what the extent of Tfr-mediated regulation is on protective immunity and HCV persistence, their presence suggests that they likely play an important role in limiting Tfh responses in the liver. Our finding that Tfr were predominantly identified in livers of chronic HCV patients and barely detectable in NVH patients suggests a role for viral infection. Whereas this phenomenon is observed in chronic HCV, it may not be exclusive to HCV given that expansion of Tfr have been reported in other viral infections, such as HIV and simian immunodeficiency virus. (39) Although beyond the scope of our study, it would be of interest to study hepatic Tfr in HCV/HIV coinfection as well as in hepatitis B virus and other hepatotrophic viral infections. Additional studies are necessary to determine the impact of Tfr on disease as well as evaluating the effects of antiviral drug treatment on their presence. Studies into how intrahepatic Tfr contribute to humoral immunity may further our understanding of antibody responses during HCV infection. Thus, novel therapeutic strategies against HCV infection could include specific agent(s) targeting Tfr-mediated immune regulation.
